Literature DB >> 22450844

Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro.

J Mani1, S Vallo, K Barth, J Makarević, E Juengel, G Bartsch, C Wiesner, A Haferkamp, R A Blaheta.   

Abstract

BACKGROUND: The influence of the bisphosphonate zoledronic acid (ZA) on prostate cancer (PC) growth, adhesion and invasive behavior was investigated.
METHODS: PC-3, DU-145 and LNCaP cells were treated with ZA, and tumor-cell growth was then investigated by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Furthermore, tumor-cell adhesion to vascular endothelium or to immobilized extracellular matrix proteins, as well as migratory properties of the cells, was evaluated. Integrin β subtypes, integrin-dependent signaling, as well as cell-cycle regulating proteins, were analyzed by western blots.
RESULTS: ZA dose-dependently reduced tumor-cell growth but did not impair tumor-endothelium and tumor-matrix interaction. However, ZA significantly inhibited tumor migration and invasive activity. Cyclin E was reduced by ZA in LNCaP and DU-145, and p21 was elevated in LNCaP cells. p27 was upregulated in all tumor cell lines, compared with the controls. ZA elevated β1-integrin in PC-3 and diminished β4-integrin in PC-3 and DU-145 cells.
CONCLUSIONS: ZA inhibits PC growth and motility but does not influence the mechanical contact between tumor cells and the vascular wall.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22450844     DOI: 10.1038/pcan.2012.9

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  9 in total

1.  Prostate cancer: New light shed on the anticancer effects of zoledronic acid.

Authors:  Melanie Clyne
Journal:  Nat Rev Urol       Date:  2012-04-24       Impact factor: 14.432

2.  Zoledronic acid augments the radiosensitivity of cancer cells through perturbing S- and M-phase cyclins and p21CIP1 expression.

Authors:  Chi Du; Yuyi Wang; Haijun Li; Yi Huang; Ou Jiang; Yanjie You; Feng Luo
Journal:  Oncol Lett       Date:  2017-08-03       Impact factor: 2.967

3.  Zoledronic acid induces apoptosis via stimulating the expressions of ERN1, TLR2, and IRF5 genes in glioma cells.

Authors:  Cigir Biray Avci; Cansu Caliskan Kurt; Burcu Erbaykent Tepedelen; Ozgun Ozalp; Bakiye Goker; Zeynep Mutlu; Yavuz Dodurga; Levent Elmas; Cumhur Gunduz
Journal:  Tumour Biol       Date:  2015-12-08

4.  The Dentin Sialoprotein (DSP) Domain Regulates Dental Mesenchymal Cell Differentiation through a Novel Surface Receptor.

Authors:  Chunyan Wan; Guohua Yuan; Daoshu Luo; Lu Zhang; Heng Lin; Huan Liu; Lei Chen; Guobin Yang; Shuo Chen; Zhi Chen
Journal:  Sci Rep       Date:  2016-07-19       Impact factor: 4.379

5.  Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

Authors:  Daniele Fanale; Valeria Amodeo; Viviana Bazan; Lavinia Insalaco; Lorena Incorvaia; Nadia Barraco; Marta Castiglia; Sergio Rizzo; Daniele Santini; Antonio Giordano; Sergio Castorina; Antonio Russo
Journal:  Oncotarget       Date:  2016-05-17

Review 6.  Peptide Self-Assembly into Hydrogels for Biomedical Applications Related to Hydroxyapatite.

Authors:  Manuel Rivas; Luís J Del Valle; Carlos Alemán; Jordi Puiggalí
Journal:  Gels       Date:  2019-03-06

Review 7.  Phosphonate and Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthases: A Structure-Guided Perspective.

Authors:  Jaeok Park; Vishal R Pandya; Sean J Ezekiel; Albert M Berghuis
Journal:  Front Chem       Date:  2021-01-06       Impact factor: 5.221

8.  RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis.

Authors:  Mark Sutherland; Andrew Gordon; Steven D Shnyder; Laurence H Patterson; Helen M Sheldrake
Journal:  Cancers (Basel)       Date:  2012-10-26       Impact factor: 6.639

Review 9.  Human isoprenoid synthase enzymes as therapeutic targets.

Authors:  Jaeok Park; Alexios N Matralis; Albert M Berghuis; Youla S Tsantrizos
Journal:  Front Chem       Date:  2014-07-22       Impact factor: 5.221

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.